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Background: A multicenter observational study was conducted in Italy to assess the safety of micafungin in the
daily clinical practice for the treatment of proven and suspected invasive candidiasis (IC), as well as to describe rates
of clinical response to micafungin treatment.
Methods: From October 2010 to March 2012, data from consecutive eligible neonate, pediatric, and adult patients
treated with micafungin for a proven or suspected IC were collected. Patients were deemed as eligible if they or
their parents signed an informed consent. The study endpoints were to assess safety of micafungin in the treatment of
both proven and suspected IC, and to describe rates of clinical response to micafungin treatment. Clinical response was
assessed at the end of micafungin treatment (EOMT) and defined as favorable (complete or partial resolution of signs
and symptoms) or unfavorable (stability or progression).
Results: During the study period, 108 patients with proven or suspected IC were enrolled. Thirty-six out of 108 patients
(33%) were < 18 year-old (median 1 year), whereas 72 (67%) were≥ 18 year-old (median 71 years). Neonates in NICU
accounted for 36% of pediatric patients, with the majority of them (54%) being extremely low birth weight (ELBW)
newborns. Fifty-eight out of 108 patients (54%) received micafungin for a proven IC, whereas 50/108 patients (46%)
were treated for a suspected IC. Among proven IC, candidemia accounted for the majority of events (54/58, 93%),
with Candida albicans (35/58, 60%) as the most frequently isolated species. Therapy was discontinued due to occurrence
of an adverse event in 4/108 subjects (4%). No pediatric patient had treatment interruption because of adverse events. A
67% favorable response rate was observed at EOMT. No age-, species-, underlying conditions- or ward-related differences
of favorable response were observed. Survival at EOMT was 90% (97/108 patients), with rates of 97% (35/36) and 86%
(62/72) among children and adults, respectively.
Conclusions: Micafungin was well tolerated in a heterogeneous real world population with a bimodal age distribution.
A high rate of favorable response to micafungin treatment was reported in both proven and suspected IC.
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Candidemia and other forms of invasive candidiasis (IC)
are a major cause of morbidity and mortality [1-7]. Inci-
dence of IC is considerably elevated among the extremes
of age, with high rates observed both in the elderly and
in premature newborns in neonatal intensive care unit
(NICU) [8-10]. Therefore, safe and effective treatment
options are needed to deal with IC in the heterogeneous
setting of the daily clinical practice.
Recent guidelines for the management of IC from the
European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) recommend an echinocandin as the
first-line treatment in IC, due to the availability of a large
amount of efficacy and safety data [11-13].
Micafungin received approval from the major regula-
tory agencies in the world (e.g., the Food and Drug
Administration, FDA, and the European Medicines
Agency, EMA) for the treatment of IC in adult and
pediatric patients including premature newborns [14].
Clinical trials involving micafungin showed response
rates ranging from 71% to 90% in the treatment of IC, and
micafungin was well tolerated and safe [15-18]. However,
tolerability of this drug in the daily clinical experience may
vary from that observed in randomized studies, due to the
heterogeneous health background of patients in the real
world practice. Therefore, a continuous post-marketing
evaluation in the real world practice is necessary to ad-
equately validate the safety of micafungin. Aim of the
present study was to prospectively evaluate safety of
micafungin for the treatment of proven and suspected
IC in different clinical conditions and centers, as well
as to describe rates of clinical response to micafungin
treatment.
Methods
From October 2010 to March 2012 a multicenter pro-
spective observational study (i.e. a post marketing multi-
center surveillance) was conducted in 38 Italian Centers.
All investigators decided the use of micafungin in any
given patient according to his/her clinical judgment
and not according to a specific protocol. They were
simply asked to record indications for the use, out-
come and tolerability. Institutional Review Boards
and/or Independent Ethics Committees at each participat-
ing center approved the study protocol (Additional file 1:
Table S1), and patients or their parents signed an in-
formed consent for the collection of the data needed
for the study.
Patient population and IC definitions
No age or other protocol-defined exclusion criteria were
defined and all patients receiving micafungin for a proven
or suspected IC were deemed as eligible, if they accepted
to sign an informed consent.Proven IC was defined as recovery of Candida spp. from
a normally sterile site in presence of signs and symptoms
of infection, according to the European Organization for
Research and Treatment of Cancer/National Institute of
Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) [19]. Suspected IC were diagnosed by
investigators according to their clinical judgment, in pres-
ence of risk factors for IC and clinical, radiological or
laboratory abnormalities (e.g., colonization, β-D-glucan)
consistent with an infectious disease process.
Study design
Consecutive eligible patients receiving micafungin for
the treatment of a proven or suspected IC were enrolled.
Safety data were collected from adult, pediatric and neo-
natal patients hospitalized in NICU, ICU, medical and
surgical wards. In addition, baseline demographic and
clinical variables, including microbiological and labora-
tory data, were recorded and response to treatment was
assessed by the investigators at the end of micafungin
treatment (EOMT).
Endpoints of the study were to evaluate tolerability of
micafungin in the treatment of proven or suspected IC,
and to describe rates of clinical response to micafungin
treatment.
Safety data was registered by the investigators and all
serious and non-serious events related to the admin-
istration of micafungin were reported. Adverse events
that were life-threatening, required initial or prolonged
hospitalization, or resulted in death, incapacity, or birth
defects were considered as serious adverse events, along
with any other event deemed as clinically significant by
investigators.
The type of response to micafungin treatment was re-
corded according to investigators’ judgment. A favorable
response was defined as complete or partial resolution
of signs and symptoms of IC, whereas treatment failure
was defined as death from any cause, progression of the
disease, or stability of attributable signs and symptoms,
reflecting standard definitions [20]. Survival was assessed
at the EOMT and at 14 days after EOMT.
Patients were treated according to local standard prac-
tice and no approved or investigational medications were
provided to the participating centers, reflecting the ob-
servational nature of the study.
Statistical analysis
Safety data, along with demographic and clinical character-
istics of patients, was provided with summary statistics.
Numbers and percentage of treatment discontinuation be-
cause of adverse events and changes in liver enzymes and
bilirubin values during treatment were also summarized.
Rates of response at the EOMT were provided for
patients’ subgroups according to age, certainty of IC,
Table 1 Baseline characteristics of patients
Variables Patients n (%)
< 18 years ≥ 18 years Total
36 (33) 72 (67) 108 (100)
Age, median (IQR) 1 (0;8) 71 (62;77) 62 (8;74)
Gender, n (%)
Male 22 (61) 42 (58) 64 (59)
Female 14 (39) 30 (42) 44 (41)
Race, n (%)
Caucasian 35 (97) 71 (99) 106 (98)
Black 1 (3) 1 (1) 2(2)
Ward of hospitalization, n (%)
Hematology* 3 (8) 4 (6) 7 (7)
Infectious diseases 1 (3) 31 (43) 32 (30)
Other medical wards** 12 (33) 10 (14) 22 (20)
Surgical 1 (3) 14 (19) 15 (14)
ICU 6 (17) 13 (18) 19 (18)
NICU 13 (36) - 13 (12)
Underlying conditions and devices,
n (%)†
Hematological malignancy 9 (25) 5 (7) 14 (13)
Solid tumor 0 13 (18) 13 (12)
Allogeneic HSCT 5 (14) 0 5 (5)
Diabetes 0 3 (4) 3 (3)
Recent Surgery 3 (8) 19 (26) 22 (20)
Presence of CVC 35 (97) 50 (69) 85 (79)
Neutropenia (missing = 6) 11 (31) 6 (9) 17 (17)
IQR, interquartile range; ICU, intensive care unit; NICU, neonatal intensive care unit;
HSCT, hematopoietic stem cell transplantation; CVC, central venous catheter.
*Including HSCT centers.
†Frequencies not mutually exclusive.
**Pediatrics (12), gastroenterology (4), nephrology (2), internal medicine (1),
oncology (1), neurology (1), pulmonology (1).
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Candida spp. responsible for proven IC, recent surgery,
presence of active malignancy, allogeneic HSCT, neutro-
penia at baseline, and ward where the diagnosis of IC
was made. Results were then compared using χ2 test or
Fisher exact test, as appropriate. All tests were 2-sided.
Relative risks (RR) with their 95% confidence intervals
(CI) were provided. Finally, summary statistics were pro-
vided for survival at EOMT and at 14 days after EOMT.
Results
During the study period, 109 patients were considered
as eligible. However, two patients (2%) were excluded
from the analyses because they did not receive any anti-
fungal treatment, and one patient was included twice in
the study, reflecting two independent IC events. A bi-
modal age distribution was observed among the 108
definitively enrolled patients, with 36 (33%) patients
being < 18 year-old (median 1 year, IQR 1–8) and 72
(67%) ≥ 18 year-old (median 71 years, IQR 62–77).
Male and female subjects were 59% (64/108) and 41%
(44/108) of the entire population, with no differences in
gender distribution between pediatric and adult subjects.
Neonates in NICU accounted for 36% of pediatric patients
(13/36), they had a median weight of 1000 g (IQR 700–
1500) and the majority of them (7/13, 54%) were extremely
low birth weight (ELBW, < 1000 g at birth) newborns.
Demographic characteristics of patients, along with distri-
butions of wards of hospitalization and underlying condi-
tions, are outlined in Table 1.
Micafungin was administered for a median of 13 days
(IQR 8–19 days), with median daily dose of 2.2 mg/kg
(IQR 2–4.1 mg/kg) and 100 mg (IQR 100–100 mg) in
children and adults, respectively. Micafungin monother-
apy was administered to 98/108 patients (91%), whereas
10/108 subjects (9%) received combined antifungal therapy.
Antifungals administered with micafungin in combined
regimens included lipid formulations of amphotericin
B (8/10, 80%), voriconazole (1/10, 10%), and fluconazole
(1/10, 10%).
Fifty-eight out of 108 patients (54%) received micafun-
gin for a proven IC, whereas 50/108 patients (46%) were
treated for a suspected IC. Among proven IC, candide-
mia accounted for the majority of events (54/58, 93%),
followed by endocarditis (3/58, 5%) and intra-abdominal
infections (1/58, 2%). Overall, Candida albicans (35/58,
60%) was the most frequently isolated species, followed by
Candida glabrata (8/58, 14%) and Candida parapsilosis
(8/58, 14%). Indeed, C. albicans was the most frequently
isolated species in adults (29/45, 64%) and children (4/6,
67%), whereas C. parapsilosis was the prevalent causative
agent of proven IC among neonates in NICU (4/7, 57%).
Details of reported IC, along with microbiological data, are
outlined in Table 2.Safety
Overall, 5 adverse drug reactions to micafungin were
reported during the study period: 4 were classified as
non-serious (anemia, rash, increasing bilirubin and ex-
acerbation of pre-existing tremor) and 1 was serious
(increase of liver enzymes). Micafungin administration
was interrupted in 12/108 patients (11%). Therapy was
discontinued due to reported ineffectiveness in 8/12 and
occurrence of an adverse event in 4/12 patients, 4% of all
treated subjects. Adverse drug reactions leading to treat-
ment discontinuation were anemia, rash, increasing bili-
rubin in a patient with pre-existing liver disease due to
chronic HCV-related hepatitis and primary biliary cirrho-
sis, and severe hepatic failure, defined by an increase in
liver enzymes plasmatic values with a concomitant re-
duction of prothrombin time. One patient developed an
exacerbation of a pre-existing tremor, but micafungin








(n = 104/108, missing = 4) 67 (70/104)
Type of IC 0.77
Proven IC 66 (37/56) 1 (ref)
Suspected IC 69 (33/48) 1.04 (0.80 - 1.36)
Therapy 0.32
Monotherapy 69 (65/94) 1 (ref)
Combined therapy† 50 (5/10) 0.72 (0.38 - 1.36)
Age 0.14
Patients < 18 years 76 (26/34) 1 (ref)
Patients≥ 18 years 63 (44/70) 0.82 (0.63 - 1.06)
Pathogen 0.76
C. albicans 68 (23/34) 1 (ref)
Non-albicans Candida spp.* 64 (14/22) 0.94 (0.64 - 1.39)
Recent surgery 0.47
Yes 60 (12/20) 1 (ref)
No 69 (58/84) 1.15 (0.78 - 1.69)
Neutropenia (missing = 6) 0.38
ANC < 500/mm3 76 (13/17) 1 (ref)
ANC≥ 500/mm3 67 (54/81) 0.87 (0.64 - 1.18)
Active malignancy 0.66
Yes** 71 (17/24) 1 (ref)
No 66 (53/80) 0.95 (0.69 - 1.26)
Allogeneic HSCT 0.75
Yes 60 (3/5) 1 (ref)
No 68 (67/99) 1.13 (0.54 - 2.34)
Ward 0.18
ICU/NICU 57 (17/30) 1 (ref)
Non-ICU/NICU 72 (53/74) 1.26 (0.89 - 1.78)
IC, invasive candidiasis; HSCT, hematopoietic stem cell transplantation; ICU, intensive
care unit; NICU, neonatal intensive care unit; ANC, absolute neutrophil count.
†lipid formulations of amphotericin B (8/10, 80%), voriconazole (1/10, 10%),
and fluconazole (1/10, 10%).
*C. parapsilosis 6/8 (75%), C. glabrata 4/7 (57%), other Candida spp. or
polymicrobial 4/7 (57%).
**Hematological (n = 9) or solid (n = 8) neoplasms.
Table 2 Micafungin for the treatment of IC in daily
clinical practice
Type of IC Patients n (%)
< 18 years ≥ 18 years Total
36 (33) 72 (67) 108 (100)
Proven IC*, n 13 45 58
Candidemia 13 41 54
Endocarditis - 3 3
Intra-abdominal infections - 1 1
Suspected IC, n 23 27 50
Diagnostic-driven therapy† 5 4 9
Empirical therapy 18 23 41
IC, invasive candidiasis.
Intra-abdominal infection was defined as Candida spp. isolation from
peritoneal fluid with clinical signs of invasive infection, according to
investigator’s clinical judgment.
*Proven IC.
Neonates (n = 7): C. parapsilosis (n = 4), C. albicans (n = 2), C. famata (n = 1).
Children (n = 6): C. albicans (n = 4), C. parapsilosis (n = 1), C. glabrata (n = 1).
Adults (n = 45): C. albicans (n = 28), C. parapsilosis (n = 3), C. glabrata (n = 6),
C. tropicalis (n = 2), C. albicans + C. glabrata (n = 1), C. guilliermondii (n = 1),
C. krusei (n = 1), C.krusei + C. lusitanie (n = 1), C. sake (n = 1), C. kefir (n = 1).
†According to mannan antigen and/or (1,3)-β-D-Glucan, which resulted
positive in 1/2 and 9/13 tested patients, respectively.
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treatment without any major trouble. No pediatric pa-
tient had treatment interruption because of adverse drug
reactions.
An increase (>2.5-fold the upper limit of normal) of
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), and bilirubin was observed in 5/60 (8%),
5/61 (8%), and 1/41 (2%) patients for whom values at
EOMT were available, respectively. In 23/95 patients
(24%, missing = 13) transaminases were higher than nor-
mal values at the beginning of micafungin administration,
and in 8/23 of them (35%) they returned within the nor-
mal range during therapy.
According to investigators’ opinion, no case of death in
this study was attributed to micafungin administration.
Response to treatment and survival rates
A favorable response was observed in 70/104 patients
(67%, missing = 4). Complete and partial response was
reported for 52/70 (74%) and 18/70 (26%) patients, re-
spectively. No age-, species-, underlying conditions- or
ward-related differences of response were observed.
However, although not statistically significant, response
was slightly lower in patients ≥ 18 years (RR 0.8, 95% CI
0.6-1.1, p = 0.14). Rates of response according to differ-
ent subgroups are summarized in Table 3.
Reported survival at EOMT was as high as 90% (97/
108 patients), with rates of 97% (35/36) and 86% (62/72)
among < 18 and ≥ 18 year-old subjects, respectively. Data
at 14 days after EOMT was available for 81/108 patients(75%, missing = 27), and an overall survival of 73% was
reported (59/81). Similarly to results at EOMT, a higher
survival at 14 days after EOMT was observed for pediatric
patients (93%, 26/28) in comparison with adult subjects
(62%, 33/53). It is worth noting that survival at 14 days
after EOMT was probably underestimated, since missing
data mostly refers to patients who early and fully recovered
from IC, and that were thus discharged home before sur-
vival assessment at 14 days after EOMT.
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The use of micafungin for the treatment of proven and
suspected IC was assessed in a multicenter prospective
and observational study performed in a real world popu-
lation with a bimodal age distribution. This type of
study, i.e. a post marketing surveillance, has the major
aim in registering adverse events in the everyday clinical
practice [21]. In this study, micafungin was well toler-
ated, with only 4% of withdrawal because of adverse
drug reactions.
Transient increases in aminotransferases are common
in safety reports regarding all echinocandins [22-24]. In
the present study, increases in transaminases values dur-
ing micafungin treatment were consistent with those ob-
served in randomized clinical trials and lower than those
observed with other antifungals such as amphotericin B
lipid formulations and voriconazole [25]. We observed
only a case of hepatic failure leading to treatment dis-
continuation, occurring in a critically ill 73-year-old pa-
tient with multiple comorbidities and receiving other
potentially hepatotoxic drugs, including amiodarone and
paracetamol, that obfuscate any potential role for mica-
fungin. We thus confirmed the already existent data of
limited hepatic toxicity after short-term micafungin ex-
posure. However, micafungin hepatic toxicity is a con-
cern that has led to an EMA warning about possible
risks of hepatic tumors, as oncogenicity was observed
in animal studies in which micafungin was used at in-
comparably higher dosages than those administered to
humans, and for a very long time [26]. Although we
understand that this warning may pose some concerns
and confusion in the medical community at least in
Europe, at recommended and approved dosages, onco-
genicity was not reproduced in clinical trials, and mica-
fungin has been used worldwide in more than one
million patients, with no post-marketing reports of hep-
atic carcinomas or adenomas related to micafungin
treatment (Astellas Global Safety Database, October
2012, data on file). In addition, the presumptive associ-
ation of catechol metabolism (one of micafungin metab-
olites [M1] carries a catechol group in its molecule) and
development of hepatocellular cancer has not been con-
firmed, and short-term exposures consistent with clinical
use did not alter the rate of cancer cell growth in a hu-
man ex vivo liver model [27]. Finally, it is unknown
whether or not long-term and high dose studies have
been performed for other echinocandins as well.
In this study, we observed rates of response to mica-
fungin treatment that were slightly lower than those re-
ported in randomized studies [15-18]. Indeed, the 63%
favorable response observed in adult patients in our
study was to some extent lower than those of 71-90% re-
ported in clinical trials [15-17]. However, demographic
variables and distribution of underlying conditions inthe real life setting are expected to vary from those of
strictly selected patients in randomized studies (e.g., ex-
clusion of subjects with reduced life expectancy, severe
organ impairment and/or receiving concomitant medi-
cations), and might explain the differences in terms of
response observed in our study. As regards pediatrics,
the rate of favorable response was 76%, consistent with
that reported by the largest available clinical trial [18].
Of note, observed survival rates in both adults and
children were comparable with those reported in clin-
ical trials and in multicenter international surveillance
studies [15-18,28,29].
Several limitations of this study have to be acknowl-
edged. First of all, some eligible patients may have re-
fused to sign an informed consent. Since the number
of patients refusing enrollment was not registered by in-
vestigators, we could not weigh the intrinsic selection
bias related to this variable. Second, the follow-up after
EOMT was reduced in comparison to clinical trials, and
possible toxicities and deaths occurring later than two
weeks after EOMT could not be reported. Finally, we
also enrolled patients with suspected IC for safety evalu-
ation, in line with the study major aim. Therefore, an in-
accurate classification of disease could have occurred in
some of these cases. This possibility, along with the ab-
sence of a comparator arm, prevented from an appropri-
ate analysis of micafungin effectiveness. However, this
was not a comparative study and our primary purpose
was to describe the safety of micafungin among patients
with both proven and suspected infections in the daily
clinical practice. Rates of response were provided only as
complementary informative data. Therefore, any inter-
pretation about micafungin effectiveness in this study
should be weighed carefully and must consider all the
aforementioned limitations.
Conclusions
In the present study, we observed a very low rate of ad-
verse events in patients with proven or suspected IC
treated with micafungin. Micafungin resulted well toler-
ated in a heterogeneous real world population with a bi-
modal age distribution. A high rate of favorable response
to micafungin treatment was reported in both proven
and suspected infections.
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